Peptide Therapeutics in Metabolic Disorders Market Analysis By 2025


Posted August 17, 2018 by jitendra

Peptide therapeutics, due to their various advantages such as high stability, selectivity, safety, efficacy, bioavailability, and tolerability offers wide applications over the other therapeutics classes.

 
Peptide therapeutics, due to their various advantages such as high stability, selectivity, safety, efficacy, bioavailability, and tolerability offers wide applications over the other therapeutics classes. Over 7,000 naturally occurring peptides have been identified, which have crucial roles in human physiology, which include hormones, neurotransmitters, growth factors, ion channel, and ligands. The structure of these peptides is usually complex and these conformations depending upon their environment.

Request for Sample Copy of Research Report@

https://www.coherentmarketinsights.com/insight/request-sample/2003



Manufacturers are focusing on developments in biologics and biopharmaceutical peptides and proteins for application in diagnostics and therapies. According to the data published in Drug Discovery Today, in January 2015, around 140 peptide therapeutics are currently evaluated in clinical trials. Peptide therapeutics are increasingly been used for therapeutics in metabolic diseases and oncology. Rising incidence of metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity are expected to be factors driving growth of the market. According to World Health Organization (WHO) 2017 data findings, the number people suffering from diabetes have increased from 108 million to 422 million in 2014. Similarly, the world obesity rate has increased three times since 1975 and in 2016, over 1.9 billion adults (18 year and above) were estimated to be overweight. Moreover, high incidence rate of metabolic disorders is expected to propel growth of peptide therapeutics in metabolic disorders market in the near future. According to the Centers for Disease Control and Prevention (CDC) October 2017 data findings, in 2011–2012, 78 million U.S. adults had low-density lipoprotein cholesterol levels, which put them at high risk of heart disease and stroke. However, high prices of products is expected to negatively impact the overall market growth.





Collaborations and new product launches:

Key players in the market are focusing on collaborations and new product launches, in order to enhance their market share. For instance, Rhythm Pharmaceuticals Inc. is engaged in developing obesity drug called setmelanotide a Melanocortin 4 receptor (MC4R) agonist peptide that is meant to be injected daily to regulate the body energy balance and appetite. Moreover, in June 2017, Rhythm Pharmaceuticals and Camurus AB released the positive initial results from ongoing Phase 1A clinical trial, which evaluated the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide. The company is also conducting trials for the treatment of extremely rare metabolic disorders such as Pro-opiomelanocortin (POMC) and Leptin receptor (LepR) deficiency obesity. Furthermore, in September, 2017, Zealand Pharma and Torrey Pines Institute for Molecular Studies entered into a research collaboration for multi-target research to identify novel peptide-based products by using Torrey Pines Institute for Molecular Studies (TPIMS’s) peptide libraries. This collaboration will help to develop specialty medicines to treat metabolic and gastrointestinal diseases.

Key players in the Peptide Therapeutics in Metabolic Disorders Market:

Some of the key players operating in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.

Global Peptide Therapeutics in Metabolic Disorders Market Taxonomy

On the basis of route of administration, peptide therapeutics in metabolic disorders market is segmented into:

Intravenous

Oral

Nasal

Others

On the basis of synthesis technology, peptide therapeutics in metabolic disorders market is segmented into:

Solid Phase Peptide Synthesis

Liquid Phase Peptide Synthesis

Hybrid Technology

On the basis of distribution channels, peptide therapeutics in metabolic disorders market is segmented into:

Hospitals

Specialty Clinics

Retail Pharmacy

Online Pharmacy

Request for Discount Before Buying This Business Reports @ https://www.coherentmarketinsights.com/insight/request-discount/2003

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702

Email:- [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By jitendra
Country United States
Categories Health
Last Updated August 17, 2018